New clinical data surrounding this compound, specifically the high-dose formulation referred to as ZPHC, suggest a impressive benefit on body mass decrease and associated chronic illnesses . Researchers posit that this dual compound, affecting both GLP-1 and GIP pathways , has the potential to provide a substantial breakthrough in the approach of